742 DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN'S DISEASE IN SUSTAINED, COMPLETE CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL

Background null It remains unknown whether infliximab (IFX) successfully can be discontinued once Crohn's disease (CD) patients have attained sustained, complete clinical, biochemical, and endoscopic remission. No randomized, placebo (PBO) controlled trial has previously assessed this. null null null Methods null This double-blind, randomized, PBO-controlled multicenter trial enrolled patients with luminal CD who had been treated with standard...